- Home
- NFBK vs DNA Comparison
NFBK vs DNA Comparison
Compare NFBK & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- DNA
- Stock Information
- Founded
- NFBK 1887
- DNA 2008
- Country
- NFBK United States
- DNA United States
- Employees
- NFBK N/A
- DNA N/A
- Industry
- NFBK Major Banks
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NFBK Finance
- DNA Health Care
- Exchange
- NFBK Nasdaq
- DNA Nasdaq
- Market Cap
- NFBK 496.7M
- DNA 731.1M
- IPO Year
- NFBK 2007
- DNA N/A
- Fundamental
- Price
- NFBK $11.45
- DNA $11.08
- Analyst Decision
- NFBK Buy
- DNA Hold
- Analyst Count
- NFBK 2
- DNA 2
- Target Price
- NFBK $13.00
- DNA $9.50
- AVG Volume (30 Days)
- NFBK 153.5K
- DNA 1.6M
- Earning Date
- NFBK 10-22-2025
- DNA 11-11-2025
- Dividend Yield
- NFBK 4.60%
- DNA N/A
- EPS Growth
- NFBK 28.89
- DNA N/A
- EPS
- NFBK 0.86
- DNA N/A
- Revenue
- NFBK $133,079,000.00
- DNA $230,815,000.00
- Revenue This Year
- NFBK $8.04
- DNA N/A
- Revenue Next Year
- NFBK $23.35
- DNA $14.41
- P/E Ratio
- NFBK $13.12
- DNA N/A
- Revenue Growth
- NFBK 4.86
- DNA 25.21
- 52 Week Low
- NFBK $9.40
- DNA $5.00
- 52 Week High
- NFBK $14.39
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- NFBK 47.04
- DNA 47.46
- Support Level
- NFBK $11.49
- DNA $9.87
- Resistance Level
- NFBK $11.99
- DNA $11.97
- Average True Range (ATR)
- NFBK 0.27
- DNA 0.80
- MACD
- NFBK -0.06
- DNA -0.09
- Stochastic Oscillator
- NFBK 17.86
- DNA 37.64
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.